{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:10:05Z","timestamp":1792102205416,"version":"4.4.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.urolonc.2024.11.017","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T01:47:16Z","timestamp":1733968036000},"page":"268.e9-268.e26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["FOXP3\/TLS; a prognostic marker in patients with bladder carcinoma without muscle invasion"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3386-2075","authenticated-orcid":false,"given":"Onur Yazdan","family":"Bal\u00e7\u0131k","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2024.11.017_bib0001","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0002","first-page":"1405","article-title":"[Diagnosis and treatment of bladder and prostate cancer in early stages]","volume":"54","author":"Watanabe","year":"1996","journal-title":"Nihon Rinsho Jpn J Clin Med"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0003","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0004","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0005","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrurol.2017.16","article-title":"BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG","volume":"14","author":"Kamat","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0006","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00114","article-title":"Comparative analysis of durable responses on immune checkpoint inhibitors versus other systemic therapies: a pooled analysis of phase III trials","volume":"3","author":"Pons-Tostivint","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0008","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0010","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0011","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/imm.13520","article-title":"Human FOXP3 and tumour microenvironment","volume":"168","author":"Wang","year":"2023","journal-title":"Immunology"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0012","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.cell.2007.04.034","article-title":"FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2\/ErbB2 oncogene","volume":"129","author":"Zuo","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0013","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1038\/bjc.2014.47","article-title":"High FoxP3 expression in tumour cells predicts better survival in gastric cancer and its role in tumour microenvironment","volume":"110","author":"Ma","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0014","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ccr.2009.08.016","article-title":"Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate","volume":"16","author":"Wang","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0015","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1002\/eji.201344392","article-title":"Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T cells","volume":"44","author":"Gautron","year":"2014","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0016","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0017","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.coi.2010.02.005","article-title":"Features of responding T cells in cancer and chronic infection","volume":"22","author":"Kim","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0018","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.it.2011.05.003","article-title":"Emerging Tim-3 functions in antimicrobial and tumor immunity","volume":"32","author":"Sakuishi","year":"2011","journal-title":"Trends Immunol"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0019","first-page":"154","article-title":"Immune Co-inhibitory receptors CTLA-4, PD-1, TIGIT, LAG-3, and TIM-3 in upper tract urothelial carcinomas: A large cohort study","volume":"46","author":"Jin","year":"2023","journal-title":"J Immunother Hagerstown Md 1997"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0020","doi-asserted-by":"crossref","first-page":"e901","DOI":"10.1016\/j.clbc.2022.08.005","article-title":"Tumor-infiltrating lymphocytes (TIL), tertiary lymphoid structures (TLS), and expression of PD-1, TIM-3, LAG-3 on TIL in invasive and In situ ductal breast carcinomas and their relationship with prognostic factors","volume":"22","author":"Acar","year":"2022","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0021","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.3390\/cells12151939","article-title":"Intratumoral PD1+CD38+Tim3+ CD8+ T cells in pre-BCG tumor tissues are associated with poor responsiveness to BCG immunotherapy in patients with non-muscle invasive bladder cancer","volume":"12","author":"Basak","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0022","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1502128","article-title":"TIM-3 expression in breast cancer","volume":"7","author":"Burugu","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0023","doi-asserted-by":"crossref","first-page":"8869","DOI":"10.1038\/s41598-017-09484-8","article-title":"Low TIM3 expression indicates poor prognosis of metastatic prostate cancer and acts as an independent predictor of castration resistant status","volume":"7","author":"Wu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0024","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/jso.24012","article-title":"T-cell immunoglobulin mucin-3 expression in bladder urothelial carcinoma: clinicopathologic correlations and association with survival","volume":"112","author":"Yang","year":"2015","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0025","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/s41423-020-0457-0","article-title":"Tertiary lymphoid structures in cancer - considerations for patient prognosis","volume":"17","author":"Munoz-Erazo","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.689270","article-title":"Tertiary lymphoid structures in cancer: the double-edged sword role in antitumor immunity and potential therapeutic induction strategies","volume":"12","author":"Kang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109422","article-title":"Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts","volume":"36","author":"Rodriguez","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0028","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.it.2014.09.006","article-title":"Tertiary lymphoid structures in cancer and beyond","volume":"35","author":"Dieu-Nosjean","year":"2014","journal-title":"Trends Immunol"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0029","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/s41416-021-01307-y","article-title":"Tertiary lymphoid structure score: a promising approach to refine the TNM staging in resected non-small cell lung cancer","volume":"124","author":"Rakaee","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.973085","article-title":"Impact of mature tertiary lymphoid structures on prognosis and therapeutic response of Epstein-Barr virus-associated gastric cancer patients","volume":"13","author":"Yin","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0031","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s00262-019-02407-8","article-title":"The prognostic significance of peritumoral tertiary lymphoid structures in breast cancer","volume":"68","author":"Sofopoulos","year":"2019","journal-title":"Cancer Immunol Immunother CII"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0032","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0033","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0034","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/0394632015584733","article-title":"Immunohistochemical pattern of T lymphocytes population within bilharzial-associated bladder neoplasm microenvironment","volume":"28","author":"El-Aal","year":"2015","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0035","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4111\/icu.2018.59.5.285","article-title":"Immune checkpoint inhibitors for urothelial carcinoma","volume":"59","author":"Kim","year":"2018","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0036","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1080\/15384047.2016.1235666","article-title":"Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse","volume":"17","author":"Nardone","year":"2016","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0037","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/nm.3708","article-title":"Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy","volume":"20","author":"Sistigu","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0038","first-page":"7781","article-title":"Prognostic and predictive significance of GITR in metastatic renal cell carcinoma","volume":"27","author":"Bal\u00e7\u0131k","year":"2023","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0039","doi-asserted-by":"crossref","first-page":"950","DOI":"10.3389\/fphys.2017.00950","article-title":"The clinicopathological and prognostic implications of FoxP3+ regulatory T cells in patients with colorectal cancer: a meta-analysis","volume":"8","author":"Xu","year":"2017","journal-title":"Front Physiol"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0040","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/path.5830","article-title":"BCG invokes superior STING-mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer","volume":"256","author":"Lombardo","year":"2022","journal-title":"J Pathol"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0041","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1158\/2326-6066.CIR-16-0267","article-title":"Intravesical BCG induces CD4+ T-cell expansion in an immune competent model of bladder cancer","volume":"5","author":"Kates","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0042","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final results of neoadjuvant Atezolizumab in Cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder","volume":"82","author":"Szabados","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0043","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12967-023-03949-3","article-title":"Tumor-associated macrophages and tregs influence and represent immune cell infiltration of muscle-invasive bladder cancer and predict prognosis","volume":"21","author":"Koll","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0044","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1158\/2326-6066.CIR-17-0466","article-title":"Urinary bladder cancer tregs suppress MMP2 and potentially regulate invasiveness","volume":"6","author":"Winerdal","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0045","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/bju.15582","article-title":"Predictive value of immunological markers after bacille Calmette-Gu\u00e9rin induction in bladder cancer","volume":"130","author":"Elsawy","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0046","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.humpath.2019.04.003","article-title":"Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladder","volume":"89","author":"Eich","year":"2019","journal-title":"Hum Pathol"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0047","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1111\/j.1464-410X.2010.10020.x","article-title":"FOXP3 and survival in urinary bladder cancer","volume":"108","author":"Winerdal","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0048","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204745","article-title":"Prediction of intravesical recurrence of non-muscle-invasive bladder cancer by evaluation of intratumoral Foxp3+ T cells in the primary transurethral resection of bladder tumor specimens","volume":"13","author":"Murai","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0049","doi-asserted-by":"crossref","first-page":"39916","DOI":"10.18632\/oncotarget.9537","article-title":"Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Gu\u00e9rin therapy in bladder cancer","volume":"7","author":"Pichler","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0050","doi-asserted-by":"crossref","first-page":"e1402","DOI":"10.1002\/cti2.1402","article-title":"Detailed bladder cancer immunoprofiling reveals new clues for immunotherapeutic strategies","volume":"11","author":"Viveiros","year":"2022","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0051","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00345-015-1615-3","article-title":"The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer","volume":"34","author":"Horn","year":"2016","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0052","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.euros.2024.06.011","article-title":"Fibroblast activation protein-\u03b1 and the Immune landscape: unraveling T1 non-muscle-invasive bladder cancer progression","volume":"66","author":"Muilwijk","year":"2024","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0053","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1111\/cas.15976","article-title":"Tertiary lymphoid structure and neutrophil-lymphocyte ratio coordinately predict outcome of pembrolizumab","volume":"114","author":"Komura","year":"2023","journal-title":"Cancer Sci"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0054","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/s41416-024-02598-7","article-title":"Synergistic induction of tertiary lymphoid structures by chemoimmunotherapy in bladder cancer","volume":"130","author":"Zhang","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0055","doi-asserted-by":"crossref","first-page":"e248","DOI":"10.1093\/oncolo\/oyad283","article-title":"Presence, subtypes, and prognostic significance of tertiary lymphoid structures in urothelial carcinoma of the bladder","volume":"29","author":"Ma","year":"2024","journal-title":"The Oncologist"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0056","doi-asserted-by":"crossref","first-page":"450.e13","DOI":"10.1016\/j.urolonc.2024.06.010","article-title":"Prognostic and predictive value of tertiary lymphoid structures in TURBT materials: should it be seated in the routine pathological examination, and can it be used in deciding on the treatment method?","volume":"42","author":"Y\u0131lmaz","year":"2024","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0057","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s00262-022-03353-8","article-title":"Preventive effect of tertiary lymphoid structures on lymph node metastasis of lung adenocarcinoma","volume":"72","author":"Wakasu","year":"2023","journal-title":"Cancer Immunol Immunother CII"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0058","article-title":"The distribution and maturation of tertiary lymphoid structures can predict clinical outcomes of patients with gastric adenocarcinoma","volume":"15","author":"Sun","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0059","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003883","article-title":"Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer","volume":"10","author":"Masuda","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0060","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s00262-011-1191-3","article-title":"FOXP3+ cell density in lymphoid follicles from histologically normal mucosa is a strong prognostic factor in early stage colon cancer","volume":"61","author":"Salama","year":"2012","journal-title":"Cancer Immunol Immunother CII"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0061","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10585-016-9813-y","article-title":"Tumor-infiltrating lymphocyte subsets and tertiary lymphoid structures in pulmonary metastases from colorectal cancer","volume":"33","author":"Schweiger","year":"2016","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0062","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00535-022-01939-8","article-title":"Integrated analysis of tertiary lymphoid structures in relation to tumor-infiltrating lymphocytes and patient survival in pancreatic ductal adenocarcinoma","volume":"58","author":"Tanaka","year":"2023","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0063","article-title":"Peritumoral tertiary lymphoid structures correlate with protective immunity and improved prognosis in patients with hepatocellular carcinoma","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0064","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3390\/cancers14030615","article-title":"Immune microenvironment characteristics of urachal carcinoma and its implications for prognosis and immunotherapy","volume":"14","author":"Zhang","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0065","doi-asserted-by":"crossref","first-page":"e1489","DOI":"10.1002\/cti2.1489","article-title":"Infiltrating characteristics and prognostic value of tertiary lymphoid structures in resected gastric neuroendocrine neoplasm patients","volume":"13","author":"Cai","year":"2024","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0066","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4149\/neo_2014_006","article-title":"Prognostic implication of TIM-3 in clear cell renal cell carcinoma","volume":"61","author":"Yuan","year":"2014","journal-title":"Neoplasma"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0067","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001823","article-title":"Intratumoral CXCL13+CD8+T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma","volume":"9","author":"Dai","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0068","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.immuni.2019.01.020","article-title":"Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer","volume":"50","author":"Wing","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0069","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.3390\/jcm13123620","article-title":"Prognostic role of OX40, LAG-3, TIM-3 and PD-L1 expression in bone and soft tissue sarcomas","volume":"13","author":"K\u0130","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0070","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1158\/1078-0432.CCR-18-4142","article-title":"Expression analysis and significance of PD-1, LAG-3, and TIM-3 in Human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis","volume":"25","author":"I","year":"2019","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0071","first-page":"1182","article-title":"Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia","volume":"33","author":"J","year":"2020","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0072","doi-asserted-by":"crossref","first-page":"784","DOI":"10.7150\/jca.14549","article-title":"PD-L1 expression is associated with tumor FOXP3(+) regulatory T-cell infiltration of breast cancer and poor prognosis of patient","volume":"7","author":"Z","year":"2016","journal-title":"J Cancer"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0073","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.7150\/jca.18683","article-title":"PD-L1 Expression Is Associated with FOXP3+ Regulatory T-Cell Infiltration of Soft Tissue Sarcoma and Poor Patient Prognosis","volume":"8","author":"Que","year":"2017","journal-title":"J Cancer"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0074","unstructured":"Tim-3 expression defines regulatory T cells in human tumors - PubMed n.d. https:\/\/pubmed.ncbi.nlm.nih.gov\/23526963\/ (accessed October 10, 2024)."},{"key":"10.1016\/j.urolonc.2024.11.017_bib0075","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3389\/fimmu.2019.00453","article-title":"Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma","volume":"10","author":"Khair","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.urolonc.2024.11.017_bib0076","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-023-01714-0","article-title":"Regulatory cells and the effect of cancer immunotherapy","volume":"22","author":"Iglesias-Escudero","year":"2023","journal-title":"Mol Cancer"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924007506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924007506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T23:43:08Z","timestamp":1741650188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924007506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1078143924007506"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.11.017","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FOXP3\/TLS; a prognostic marker in patients with bladder carcinoma without muscle invasion","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.11.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}